Vitamin E in Neurodegenerative Disorders: Alzheimer's Disease
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
A bstract: Oxidative stress is important in the pathogenesis of Alzheimer's disease (AD). The brain contains high levels of oxidizable lipids that must be protected by antioxidants. Low concentrations of vitamin E, quantitatively the major lipophilic antioxidant in the brain, are frequently observed in cerebrospinal fluid (CSF) of AD patients, suggesting that supplementation with vitamin E might delay the development of AD. In a placebo‐controlled trial, vitamin E (2000 IU/day, 2 years) slowed (−53%) functional deterioration in patients with moderate AD (Sano et al., N. Engl. J. Med. 336: 1216‐1222, 1997). Recently, use of vitamin E and vitamin C supplements in combination was found to be associated with reduced prevalence (−78%) and incidence (−64%) of AD in elderly population (Zandi et al., Arch. Neurol. 61: 82‐88, 2004). These results are consistent with the ability of the supplementation with vitamin E (400 IU/day, 1 month) to increase its levels in CSF (123%) and plasma (145%) of AD patients and, in combination with vitamin C (1000 g/day), to decrease the susceptibility of CSF lipoproteins (up to −32%) to in vitro oxidation (Kontush et al., Free Radic. Biol. Med. 31: 345‐354, 2001). In addition, vitamin E reduced lipid peroxidation and amyloid deposition in a transgenic mice model of AD (Sung et al., FASEB J. 18: 323‐325, 2004). Computer modeling of the influence of vitamin E on lipoprotein oxidation reveals that the vitamin develops antioxidative activity in CSF lipoproteins in the presence of physiologically relevant, low amounts of oxidants. By contrast, under similar conditions, vitamin E behaves as a pro‐oxidant in plasma lipoproteins, consistent with the model of tocopherol‐mediated peroxidation (Stocker, Curr. Opin. Lipidol. 5: 422‐433, 1994). This distinction is related to major differences in the levels of vitamin E (50 nM vs. 30 μM) and oxidizable lipids (4 μM vs. 2.5 mM) between CSF and plasma, which result in major differences in oxidative conditions (per unit of vitamin E) between CSF and plasma in the presence of similar amounts of oxidants. Altogether, these data suggest that vitamin E may be effective against in vivo oxidation of CSF lipoproteins and brain lipids, and offer new perspectives in the treatment of AD and other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Dietary Intake of Antioxidants and Risk of Alzheimer Disease
Engelhart, M. J. (2002) · JAMA · doi:10.1001/jama.287.24.3223 · Cited by 1,080
Oxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Allan Butterfield, D. (2002) · Free Radical Research · doi:10.1080/1071576021000049890 · Cited by 786
Morris, M. C. (2002) · JAMA · doi:10.1001/jama.287.24.3230 · Cited by 678
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414
Increased F 2 ‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo
Pratico, D., Lee, V. M.-Y., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.15.1777 · Cited by 405
Vitamin E and Vitamin C Supplement Use and Risk of Incident Alzheimer Disease
Morris, M. C., Beckett, L. A., Scherr, P. A., Hebert, L. E., Bennett, D. A., Field, T. S., & Evans, D. A. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00001 · Cited by 332
Association of vitamin E and C supplement use with cognitive function and dementia in elderly men
Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H., Havlik, R., & White, L. R. (2000) · Neurology · doi:10.1212/wnl.54.6.1265 · Cited by 330
Zou, K., Gong, J.-S., Yanagisawa, K., & Michikawa, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-12-04833.2002 · Cited by 305
Cited by
Jomova, K., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03696-4 · Cited by 1,445
“The nervous system is the most vulnerable to vitamin E deficiency (Kontush and Schekatolina 2004).”
BackgroundMetals, oxidative stress and neurodegenerative disorders
Jomova, K., Vondrakova, D., Lawson, M., & Valko, M. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0563-x · Cited by 1,052
Oxidative stress in Alzheimer’s disease
Chen, Z., & Zhong, C. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1423-y · Cited by 797
“Picomolar or low nanomolar levels of Aβ are neurotrophic or neuroprotective([92]), effi ciently suppress the auto-oxidation of lipoproteins in the CSF and plasma([93]), and dramatically increase hippocampal long-term potentiation([94]), whereas high nanomolar concentrations induce the wellestablished neurotoxicity.”
BackgroundAntioxidant Therapies for Alzheimer's Disease
Feng, Y., & Wang, X. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/472932 · Cited by 379
Elnaggar, Y. S. R., Etman, S. M., Abdelmonsif, D. A., & Abdallah, O. Y. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24557 · Cited by 327
Oxidative stress mediates tau-induced neurodegeneration in Drosophila
Dias-Santagata, D., Fulga, T. A., Duttaroy, A., & Feany, M. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28769 · Cited by 318
“Clinical trials using antioxidants and, more specifically, vitamin E yielded conflicting results regarding the suitability of this drug for the treatment of AD and other neurodegenerative diseases (31, 44, 45).”
ResultChonpathompikunlert, P., Wattanathorn, J., & Muchimapura, S. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.12.009 · Cited by 291
Cognitive enhancement and neuroprotective effects of Bacopa monnieri in alzheimer’s disease model
Uabundit, N., Wattanathorn, J., Mucimapura, S., & Ingkaninan, K. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.09.056 · Cited by 282
Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., & Riederer, P. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0877-9 · Cited by 272
Melatonin in Alzheimer's disease and other neurodegenerative disorders
Srinivasan, V, Pandi-Perumal, Sr., Cardinali, D., Poeggeler, B., & Hardeland, R. (2006) · Behavioral and Brain Functions · doi:10.1186/1744-9081-2-15 · Cited by 223
Kang, J. H., Cook, N. R., Manson, J. E., Buring, J. E., Albert, C. M., & Grodstein, F. (2009) · Circulation · doi:10.1161/circulationaha.108.816900 · Cited by 136
Alabdali, A., Al-Ayadhi, L., & El-Ansary, A. (2014) · Behavioral and Brain Functions · doi:10.1186/1744-9081-10-14 · Cited by 101
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort
Ravaglia, G., Forti, P., Lucicesare, A., Pisacane, N., Rietti, E., Mangialasche, F., Cecchetti, R., Patterson, C., & Mecocci, P. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.5.1306 · Cited by 59
Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders
Turri, M., Marchi, C., Adorni, M. P., Calabresi, L., & Zimetti, F. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159123 · Cited by 54
Metadata
- Authors
- KONTUSH, A., & SCHEKATOLINA, S.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 1031
- Issue
- 1
- Pages
- 249-262
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2115028049
- Cited by
- 131
- References
- 14
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.